alexion-pharmaceuticals

Alexion Pharmaceuticals was a global biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing life-transforming therapies for rare diseases. Founded in 1992, the company pioneered complement inhibition therapy and developed leading treatments for rare hematological and neurological conditions including Soliris (eculizumab) and Ultomiris (ravulizumab). AstraZeneca acquired Alexion in July 2021 for $39 billion, and the company now operates as Alexion, AstraZeneca Rare Disease. The combined entity maintains research programs in complement biology, hematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Alexion's GitHub organization (alxndgb) hosts research tools including genomic data analysis platforms, precision medicine knowledge graphs, and rare disease target discovery systems.